117 results on '"Galetta, D."'
Search Results
2. A cross-sectional study evaluating the exercise discussion with oncologist during cancer consultation: the CONNECT study
3. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1
4. Prognostic value of PET parameters in patients with pleomorphic lung cancer: Results from a single institution
5. The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma
6. The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma
7. The IASLC Mesothelioma Staging Project: Improving Staging of a Rare Disease Through International Participation
8. LBA2 First-line (1L) durvalumab (D) + platinum-etoposide (EP) for patients (pts) with extensive-stage SCLC (ES-SCLC): Primary results from the phase IIIb LUMINANCE study
9. P4.14C.04 Exhaled Breath Analysis for the Early Diagnosis of Malignant Pleural Mesothelioma and the Surveillance of Asbestos-Exposed At-Risk Subjects
10. MA04.08 High Recruitment Rate and Performance of a National Lung Cancer Screening Network Implementing Web-Based Instruments
11. 1912P AI-based early prediction of radiation pneumonitis in stage III NSCLC patients
12. 1689TiP The social stigma of smokers and patients with lung cancer: Detection of phoenomenon and testing of EMDR (eye movement desensitization and reprocessing) intervention
13. 1283P Advanced ALK-positive non-small cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database
14. Cisplatin, fotemustine and whole-brain radiotherapy in non-small cell lung cancer patients with asymptomatic brain metastases: A multicenter phase II study of the Gruppo Oncologico Italia Meridionale (GOIM 2603)
15. Maintenance or non-maintenance therapy in the treatment of advanced non-small cell lung cancer: that is the question
16. EP06.03-18 Atlas: Italian Knowledge Based Database for Biomarkers Analysis In NSCLC Patients
17. EP04.01-02 Volatile Organic Compounds in Exhaled Breath as Biomarkers for Lung Cancer. A Screening-Based Study in High-Risk Participants
18. EP01.01-12 Binge-Watching Frequency and Tobacco Use in Adolescents: Data from “Blaam Smoke-Free Movie” Program
19. MA07.09 Adapted Physical Activity (AMAti) Program for Lung Cancer Patients Realized by WALCE (Women Against Lung Cancer in Europe)
20. 1510TiP Efficacy study of osimertinib in treatment-naïve patients with EGFR mutant non-small cell lung cancer (NSCLC) according to TP53 mutational status (TEMPLE-2/NCT05785208)
21. 2001P Consolidative thoracic radiotherapy of extensive-stage small cell lung cancer in the era of chemoimmunotherapy: A retrospective analysis concerning patients from southern Italy
22. 2128P exerCise discussion with Oncologist duriNg caNcEr ConsultaTion: The CONNECT study
23. 92P Predictors, surrogate and patient-reported outcomes in neoadjuvant immunotherapy for lung cancer: A single-center retrospective study
24. Neoadjuvant concurrent radiochemotherapy in locally advanced (IIIA–IIIB) non-small-cell lung cancer: long-term results according to downstaging
25. EP08.02-101 Real-world Data from KRAS-mutant Advanced NSCLC: the ATLAS Multicenter Cohort Study
26. EP08.02-048 Crizotinib in ROS1+NSCLC: Long-term OS Analysis in Patients with Brain Metastases Included in the Phase II METROS Trial
27. EP02.04-001 Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-Positive NSCLC: ALNEO Phase II Trial (GOIRC-01-2020)
28. P2.10-05 Circulating CD3+CD56+ Cells as a Biomarker for Immunotherapy in SCLC.
29. P2.14-02 TP53 Mutations Affect Sensitivity to Lorlatinib in ROS1 Positive NSCLC: Final Results of the PFROST Trial
30. 1019P Pattern of clinical activity of anticancer vaccine OSE2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO) in phase III Atalante-1 randomized trial
31. 125P Radiomic signature from baseline CT Scan to predict initial response to treatment in advanced/unresectable pleural mesothelioma: Preliminary data
32. LBA47 Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO): Final results of phase III Atalante-1 randomised trial
33. 104P Fast progression in high PD-L1 NSCLC treated with pembrolizumab in first-line: A prognostic scoring system based on clinical features
34. P75.21 Impact of Diagnosis and Treatment of Concurrent Infections during Immunotherapy in Advanced Lung Cancer: A Retrospective Cohort Study
35. P78.12 A Rare Case of Dermatomyositis as Late Immune-Related Toxicity During Anti-PD1 Treatment for Advanced Lung Cancer
36. P75.14 Gender-Related Safety and Outcome in Advanced NSCLC Patients Treated with Immune Checkpoint-Inhibitors. A Real-World Experience
37. P40.01 Tobacco use in Adolescence and Associated Factors: Products, School, Family, Peers and Movies in Pandemic Period
38. FP06.04 Psychological Distress in Outpatients with Lymphoma, Lung and Breast Cancer during COVID-19 pandemic
39. 1260MO Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial
40. 134 - Baseline neutrophil-to-lymphocyte ratio and PD-L1 expression level or LDH value may predict outcome of patients with high PD-L1 advanced non-small cell lung cancer treated with first-line pembrolizumab
41. 55P - Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: A multicenter study
42. EP1.17-19 Robotic-Assisted Thoracic Surgery for Early Stage Lung Cancer: Ten Years' Single Institution Experience
43. EP1.04-38 A Case of Lichenoid Reaction as Late and Uncommon Immune-Related Skin Toxicity During Nivolumab Treatment
44. EP1.01-81 Resection of Tumors with Carinal Involvement After Induction Therapy
45. EP1.01-56 Co-Presentation of Adenocarcinoma and Squamous Cell Lung Carcinoma Harbouring ALK Rearrangement in Different Sites
46. EP1.01-44 Early and Long-Term Results of Tracheal Sleeve Pneumonectomy for Lung Cancer After Induction Therapy
47. EP1.01-01 Atrial Resection Without Cardiopulmonary Bypass for Lung Cancer
48. P2.10-06 Smoking Prevalence and Perceptions Among Healthcare Professionals: A Survey in an Italian Clinical Cancer Centre
49. P2.04-14 NLR, dNLR and PLR as Possible Predictive Markers in Patients with NSCLC Treated with ICI
50. P2.04-07 Surgical Resection of Advanced Lung Cancer After a Response to EGFR-TKI and/or Immunotherapy: A Single Institution Experience
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.